Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 15
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

“Be sustainable”: EOSC‐Life recommendations for implementation of FAIR principles in life science data handling

  • David, Romain
  • Lancelotti, Carla
  • Gribbon, Philip
Includes supplementary materials for the online appendix., The main goals and challenges for the life science communities in the Open Science framework are to increase reuse and sustainability of data resources, software tools, and workflows, especially in large‐scale data‐driven research and computational analyses. Here, we present key findings, procedures, effective measures and recommendations for generating and establishing sustainable life science resources based on the collaborative, cross‐disciplinary work done within the EOSC‐Life (European Open Science Cloud for Life Sciences) consortium. Bringing together 13 European life science research infrastructures, it has laid the foundation for an open, digital space to support biological and medical research. Using lessons learned from 27 selected projects, we describe the organisational, technical, financial and legal/ethical challenges that represent the main barriers to sustainability in the life sciences. We show how EOSC‐Life provides a model for sustainable data management according to FAIR (findability, accessibility, interoperability, and reusability) principles, including solutions for sensitive‐ and industry‐related resources, by means of cross‐disciplinary training and best practices sharing. Finally, we illustrate how data harmonisation and collaborative work facilitate interoperability of tools, data, solutions and lead to a better understanding of concepts, semantics and functionalities in the life sciences., This research is mainly a product of the EOSC‐Life European programme funding from the European Union's Horizon Europe Research and Innovation Programme under grant agreement No. 824087. Complementary support was provided through: EU funded project AgroServ (grant agreement No. 101058020), EU funded project BY‐COVID (grant agreement No. 101046203), EU funded project DANUBIUS‐IP (grant agreement No. 101079778), EU funded project EMPHASIS‐GO (grant agreement No. 101079772), EU funded project FAIRplus (IMI grant agreement No. 802750), EU funded project FAIRsharing (Wellcome grant agreement No. 212930/Z/18/Z), EU funded project ISIDORe (grant agreement No. 101046133), EU funded project Precision Toxicology (grant agreement No. 965406), UKRI DASH (grant agreement No. MR/V038966/1). Special thanks to T. Biro and her radical collaboration team from Research Data Alliance who gave us great inspiration on how to lead this radical collaboration work.Thanks are also due to Martina Esdaile for proofreading the final version of the manuscript. Open access funding enabled and organized by Projekt DEAL.
IRTA Pubpro. Open Digital Archive
Publication Artículo científico (JournalArticle)

An ACE2-Fc decoy produced in glycoengineered plants neutralizes ancestral and newly emerging SARS-CoV-2 variants and demonstrates therapeutic efficacy in hamsters

  • Föderl-Höbenreich, Esther
  • Izadi, Shiva
  • Hofacker, Lara
  • Kienzl, Nikolaus F.
  • Castilho, Alexandra
  • Strasser, Richard
  • Tarrés Freixas, Ferran
  • Cantero Portillo, Guillermo
  • Roca, Núria
  • Pérez Maíllo, Mónica
  • Lorca-Oró, Cristina
  • Usai, Carla
  • Segalés, Joaquim
  • Vergara-Alert, Júlia
  • Mach, Lukas
  • Zatloukal, Kurt
Newly emerging SARS-CoV-2 variants of concern (VOCs) continue to drive COVID-19 waves and are typically associated with immune escape and increased resistance to current therapeutics including monoclonal antibodies. By contrast, VOCs still display strong binding to the host cell receptor ACE2. Consistent with these properties, we have now found that a soluble ACE2-Fc decoy produced in glycoengineered plants effectively neutralizes different SARS-CoV-2 isolates and exhibits even increased potency against VOCs as compared to an ancestral virus strain. In a golden Syrian hamster model, therapeutic intranasal delivery of ACE2-Fc effectively reduced weight loss and SARS-CoV-2 replication in the lungs when administered 24 h post-inoculation. This protective effect was not observed upon treatment of the infected animals with a non-binding ACE2-Fc mutant, demonstrating that the plant-derived ACE2-Fc decoy interferes specifically with the attachment of the virus to host cells. The results obtained provide support for further development of decoy-based antiviral approaches by plant molecular pharming., We thank Ulrike Vavra, Katharina Wolf and David Niedermayer for assistance with ACE2-Fc purification and characterization and Vinny Kunnummel for plant propagation and maintenance. We are grateful to Florian Krammer for his advice on the design of the in vivo study. This work was supported by funds from BOKU University and a Transnational Access Grant provided by ISIDORe (funded by the European Union’s Horizon Europe research and innovation program under grant agreement No. 101046133) to Zatloukal Innovations GmbH. This research was funded in part by the Austrian Science Fund (FWF) [W 1224/Grant https://doi.org/10.55776/W1224; P 31920/Grant https://doi.org/10.55776/P31920; P 35292/Grant https://doi.org/10.55776/P35292]. For open access purposes, the authors have applied a CC BY public copyright license to any accepted manuscript version arising from this submission. The SARS-CoV-2 variant hCoV-19/France/GE1973/2020, clade G, D614G (S) was supplied through the European Virus Archive goes Global (EVAg) platform, a project that has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 653316., info:eu-repo/semantics/publishedVersion
IRTA Pubpro. Open Digital Archive
Publication Artículo científico (JournalArticle)

Differential impact of porcine reproductive and respiratory virus and swine Influenza A virus infections on respiratory Lymph Nodes B cells and macrophages

  • Hervet, C.
  • Perrin, A.
  • Renson, P.
  • Deblanc, C.
  • Muñoz, M.
  • Meurens, F.
  • Argilaguet, Jordi
  • Simon, G.
  • Bourry, O.
  • Maisonnasse, P.
  • Bertho, N.
Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) has a profound impact on the swine industry due to its ability to persist in infected animals. The PRRSV family exhibits considerable genetic variability, with PRRSV-1 and PRRSV-2 now classified as two distinct species (Betaarterivirus suid 1 and 2). Interestingly, both species - and their corresponding attenuated vaccine strains - can persist for months, in part by delaying the appearance of neutralizing antibodies. Leveraging recently developed tools for in-depth analysis of the previously poorly characterized porcine inverted lymph node (LN), we investigated early events in LN B cell maturation during PRRSV-1 infection and compared them to those induced by acute swine influenza A virus infection. We highlighted PRRSV-specific mechanisms, including PD-L1 upregulation in efferent macrophages, the presence of extrafollicular centrocytes, and the influx of inflammatory monocytes/macrophages. These findings are consistent with previous observations in PRRSV-2 infections and may therefore reflect conserved immune evasion mechanisms across PRRSV strains., This work was supported by the European Union’s Infrastructure Program VetBioNet (INFRA-2016–1; Nº731014) and the Horizon Europe research and innovation program ISIDORe (Grant Agreement No. 101046133). This publication reflects the views only of the authors, and does not necessarily represent those of the European Commission (EC). The EC is not responsible for any use that may be made of the information contained herein., info:eu-repo/semantics/acceptedVersion
IRTA Pubpro. Open Digital Archive
Publication Artículo científico (JournalArticle)

Boosting Vaccine Research: The 16-Year Journey of TRANSVAC Vaccine Infrastructure

  • Martin, William
  • Luís, Catarina
  • Jungbluth, Stefan
  • Slezak, Monika
  • Verreck, Frank A. W.
  • Spiegel, Holger
  • Guzman, Carlos A.
  • Roldão, António
  • Carrondo, Manuel J. T.
  • Van der Ley, Peter
  • Segalés, Joaquim
  • Dockrell, Hazel M.
  • Ho, Mei Mei
  • Pedersen, Gabriel K.
  • Lawrenz, Maria
  • Olesen, Ole F.
TRANSVAC represents a long-running effort to accelerate the development of novel vaccines by integrating institutions from across Europe under a single collaborative framework. This initiative has empowered the global vaccine community since 2009 including contributing toward the development and optimization of vaccine candidates as well as the provision of new adjuvants, research protocols, and technologies. Scientific services were provided in support of 88 different vaccine development projects, and 400 professionals attended TRANSVAC training events on various vaccine-related topics. Here, we review the accomplishments of the TRANSVAC consortia and analyze the continued needs of academic and industrial vaccine developers in Europe. The findings highlight the benefits of coordination across different sectors, both through research infrastructures such as TRANSVAC and other mechanisms, to address the current and future global health challenges and ensure that European vaccine developers have the support required to successfully compete in the global market., TRANSVAC was supported by the EU FP7 project TRANSVAC (FP7-INFRASTRUCTURES-2008-228403). TRANSVAC2 received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement no. 730964. ISIDORe received funding from the European Union’s Horizon Europe research and innovation program under grant agreement number 101046133., info:eu-repo/semantics/publishedVersion
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Umbrella Data Management Plans to Integrate FAIR Data : Lessons From the ISIDORe and BY-COVID Consortia for Pandemic Preparedness

  • Carazo, José M.
The Horizon Europe project ISIDORe is dedicated to pandemic preparedness and responsiveness research. It brings together 17 research infrastructures (RIs) and networks to provide a broad range of services to infectious disease researchers. An efficient and structured treatment of data is central to ISIDORe’s aim to furnish seamless access to its multidisciplinary catalogue of services, and to ensure that users’ results are treated FAIRly. ISIDORe therefore requires a data management plan (DMP) covering both access management and research outputs, applicable over a broad range of disciplines, and compatible with the constraints and existing practices of its diverse partners. Here, we describe how, to achieve that aim, we undertook an iterative, step-by-step, process to build a community-approved living document, identifying good practices and processes, on the basis of use cases, presented as proof of concepts. International fora such as the RDA and EOSC, and primarily the BY-COVID project, furnished registries, tools and online data platforms, as well as standards, and the support of data scientists. Together, these elements provide a path for building an umbrella, FAIR-compliant DMP, aligned as fully as possible with FAIR principles, which could also be applied as a framework for data management harmonisation in other large-scale, challenge-driven projects. Finally, we discuss how data management and reuse can be further improved through the use of knowledge models when writing DMPs and, how, in the future, an inter-RI network of data stewards could contribute to the establishment of a community of practice, to be integrated subsequently into planned trans-RI competence centres.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Recombinant Influenza A Viruses Expressing Reporter Genes from the Viral NS Segment

  • Martínez-Sobrido, Luis
  • Nogales, Aitor
Studying influenza A viruses (IAVs) requires secondary experimental procedures to detect the presence of the virus in infected cells or animals. The ability to generate recombinant (r)IAV using reverse genetics techniques has allowed investigators to generate viruses expressing foreign genes, including fluorescent and luciferase proteins. These rIAVs expressing reporter genes have allowed for easily tracking viral infections in cultured cells and animal models of infection without the need for secondary approaches, representing an excellent option to study different aspects in the biology of IAV where expression of reporter genes can be used as a readout of viral replication and spread. Likewise, these reporter-expressing rIAVs provide an excellent opportunity for the rapid identification and characterization of prophylactic and/or therapeutic approaches. To date, rIAV expressing reporter genes from different viral segments have been described in the literature. Among those, rIAV expressing reporter genes from the viral NS segment have been shown to represent an excellent option to track IAV infection in vitro and in vivo, eliminating the need for secondary approaches to identify the presence of the virus. Here, we summarize the status on rIAV expressing traceable reporter genes from the viral NS segment and their applications for in vitro and in vivo influenza research, Research in L.M.-S.’s laboratory on influenza is partially funded by the Center for Research on Influenza Pathogenesis and Transmission (CRIPT), one of the National Institute of Allergy and Infectious Diseases (NIAID) funded Centers of Excellence for Influenza Research and Response (CEIRR; contract # 75N93021C00014) and by a grant from the American Lung Association (ALA). Research in A.N.’s laboratory on influenza is partially funded by Federal Funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93021C00018 (NIAID Centers of Excellence for Influenza Research and Response, CEIRR) and the European Union’s Horizon Europe research and innovation programme (grant agreement 101046133), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Are we serologically prepared against an avian influenza pandemic and could seasonal flu vaccines help us?

  • Sanz Muñoz, Iván
  • Sánchez Martínez, Javier
  • Rodríguez Crespo, Carla
  • Concha Santos, Corina S.
  • Hernández, Marta
  • Rojo Rello, Silvia
  • Domínguez Gil, Marta
  • Mostafa, Ahmed
  • Martínez-Sobrido, Luis
  • Eiros, José M.
  • Nogales, Aitor
The current situation with H5N1 highly pathogenic avian influenza virus (HPAI) is causing a worldwide concern due to multiple outbreaks in wild birds, poultry, and mammals. Moreover, multiple zoonotic infections in humans have been reported. Importantly, HPAI H5N1 viruses with genetic markers of adaptation to mammals have been detected. Together with HPAI H5N1, avian influenza viruses H7N9 (high and low pathogenic) stand out due to their high mortality rates in humans. This raises the question of how prepared we are serologically and whether seasonal vaccines are capable of inducing protective immunity against these influenza subtypes. An observational study was conducted in which sera from people born between years 1925-1967, 1968-1977, and 1978-1997 were collected before or after 28 days or 6 months post-vaccination with an inactivated seasonal influenza vaccine. Then, hemagglutination inhibition, viral neutralization, and immunoassays were performed to assess the basal protective immunity of the population as well as the ability of seasonal influenza vaccines to induce protective responses. Our results indicate that subtype-specific serological protection against H5N1 and H7N9 in the representative Spanish population evaluated was limited or nonexistent. However, seasonal vaccination was able to increase the antibody titers to protective levels in a moderate percentage of people, probably due to cross-reactive responses. These findings demonstrate the importance of vaccination and suggest that seasonal influenza vaccines could be used as a first line of defense against an eventual pandemic caused by avian influenza viruses, to be followed immediately by the use of more specific pandemic vaccines.IMPORTANCEInfluenza A viruses (IAV) can infect and replicate in multiple mammalian and avian species. Avian influenza virus (AIV) is a highly contagious viral disease that occurs primarily in poultry and wild water birds. Due to the lack of population immunity in humans and ongoing evolution of AIV, there is a continuing risk that new IAV could emerge and rapidly spread worldwide, causing a pandemic, if the ability to transmit efficiently among humans was gained. The aim of this study is to analyze the basal protection and presence of antibodies against IAV H5N1 and H7N9 subtypes in the population from different ages. Moreover, we have evaluated the humoral response after immunization with a seasonal influenza vaccine. This study is strategically important to evaluate the level of population immunity that is a major factor when assessing the impact that an emerging IAV strain would have, and the role of seasonal vaccines to mitigate the effects of a pandemic., This project has been funded in part with Federal Funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contract no. 75N93021C00018 (NIAID Centers of Excellence for Influenza Research and Response, CEIRR). This project has been funded in part by the European Union's Horizon Europe research and innovation programme (grant agreement 101046133). This project has been funded in part by national funds from Gerencia Regional de Salud de la Junta de Castilla y León (GRS2557/A/22) and a research incorporation grant from CSIC (202240I182). Research on influenza in LMS lab was partially funded by the American Lung Association (ALA)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Use of Rift Valley Fever Virus Expressing NanoLuc Luciferase for the Assessment of Neutralizing Antibodies and Antivirals

  • Borrego, Belén
  • Martínez-Sobrido, Luis
  • Brun, Alejandro
  • Nogales, Aitor
Protocol., Rift Valley fever (RVF) is an arboviral zoonotic disease affecting many African countries with the potential to spread to other geographical areas. In this chapter we describe the use of a replication-competent recombinant (r)RVFV expressing NanoLuc Luciferase (Nluc) for in vitro studies. The determination of parameters such as neutralizing antibodies in serum samples, or the antiviral activity of drugs is usually carried out using standard assays based on the assessment of cytopathic effect on cell cultures. The use of a virus encoding a traceable reporter protein allows to correlate the presence or absence of infection with the detection of the product in the infected cultures, thus tracking the level of RVFV infection in an objective, quantitative manner. In addition to this quantitative measurement of results, our protocol offers two other advantages, such as a shorter time to read, given that 48 h post-infection the production of the reporter protein is enough to give an accurate result, and the use of an attenuated virus, which reduces the risk of exposure., Research on RVFV was funded by grant PID2021-122567OB-I00 MCIN/AEI /10.13039/501100011033/ and by ERDF “A way of making Europe.” Research was also partially funded by ISIDORe JRA Programme. ISIDORe has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement number 101046133., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Novel replication-competent reporter-expressing Rift Valley fever viruses for molecular studies

  • Nogales, Aitor
  • Alonso, Celia
  • Moreno, Sandra
  • Lorenzo, Gema
  • Borrego, Belén
  • Martínez-Sobrido, Luis
  • Brun, Alejandro
All data supporting the findings of this study are available within the paper. No data sets or new viral sequences were generated or analyzed during the current study., Rift Valley fever virus (RVFV) is a mosquito-borne zoonotic disease that causes severe disease in both domestic and wild ungulates and humans, making it a significant threat to livestock and public health. The RVFV genome consists of three single-stranded, negative-sense RNA segments differing in size: small (S), medium (M), and large (L). Segment S encodes the virus nucleoprotein N and the virulence-associated factor non-structural (NSs) protein in opposite orientations, separated by an intergenic region (IGR). To overcome the current need to use secondary techniques to detect the presence of RVFV in infected cells, we used T7-driven polymerase plasmid-based reverse genetics to generate replication-competent recombinant (r)RVFV expressing Nanoluciferase (Nluc) or Venus fluorescent proteins. These reporter genes were used as valid surrogates to track the presence of RVFV in mammalian and insect cells. Notably, we explored the genome plasticity of RVFV and compared four different strategies by modifying the viral segment S to introduce the reporter gene foreign sequences. The reporter-expressing rRVFV were stable and able to replicate in cultured mammalian and insect cells, although to a lesser extent than the recombinant wild-type (WT) counterpart. Moreover, rRVFV-expressing reporter genes were validated to identify neutralizing antibodies or compounds with antiviral activity. In vivo, all mice infected with the reporter-expressing rRVFV displayed an attenuated phenotype, although at different levels. These rRVFV-expressing reporter genes provide a novel approach to better understand the biology and pathogenesis of RVFV and represent an excellent biotechnological tool for developing new therapeutics against RVFV infections., This study was partially funded by the Ramon y Cajal Incorporation grant (RYC-2017) from the Spanish Ministry of Science, Innovation, and Universities and the European Union's Horizon Europe Research and Innovation Programme (grant agreement 101046133) and by grant PID2021-122567OB-I00 funded by MCIN/ AEI/10.13039/501100011033/and by ERDF “A way of making Europe.”, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Structural basis of poxvirus fusion regulation and anti-A16/G9 antibody-mediated neutralization and protection

  • Meola, Annalisa
  • Vernuccio, Riccardo
  • Battini, Leandro
  • Albericio, Guillermo
  • Delgado, Pilar
  • Bamford, Rebecca
  • Pokorny, Laura
  • Broutin, Manon
  • Martínez León, Alejandro
  • Gallien, Sébastien
  • Gil, María
  • Noriega, María A.
  • Guivel-Benhassine, Florence
  • Porrot, Françoise
  • Postal, Jeanne
  • Buchrieser, Julian
  • Hubert, Mathieu
  • Haouz, Ahmed
  • Lafaye, Pierre
  • Esteban, Mariano
  • Hub, Jochen S.
  • Mahévas, Matthieu
  • Chappert, Pascal
  • Mercer, Jason
  • García-Arriaza, Juan
  • Schwartz, Olivier
  • Guardado-Calvo, Pablo
Monkeypox virus (MPXV) is a poxvirus endemic to Central and West Africa with high epidemic potential. Poxviruses enter host cells via a conserved entry-fusion complex (EFC), which mediates viral fusion to the cell membrane. The EFC is a promising therapeutic target, but the absence of structural data has limited the development of fusion-inhibiting treatments. Here, we investigated A16/G9, a subcomplex of the EFC that controls fusion timing. Using cryo-electron microscopy, we showed how A16/G9 interacts with A56/K2, a viral fusion suppressor that prevents superinfection. Immunization with A16/G9 elicited a protective immune response in mice. Using X-ray crystallography, we characterized two neutralizing antibodies and engineered a chimeric antibody that cross-neutralizes several poxviruses more efficiently than 7D11, the most potent antibody targeting the EFC described to date. These findings highlight the potential of A16/G9 as a candidate for subunit vaccines and identify regions of the EFC as targets for antiviral development., Access to Diamond was funded by iNEXT-Discovery/Instruct (PID: 25820, VID: 43499) and funded by the European Union Research and Innovation programme Horizon Europe (ISIDORe—grant agreement number 101046133). The NanoImaging Core Facility at Institut Pasteur is acknowledged for support with sample preparation, image acquisition, and analysis. The NanoImaging Core was created with the help of a grant from the French Government’s Investissements d’Avenir program (EQUIPEX CACSICE - Centre d’analyse de systèmes complexes dans les environnements complexes, ANR-11-EQPX-0008). We also thank the CNB-CSIC animal facility for help and assistance, Marija Backovic for useful discussions on the serpin assay, and Pierre Legrand for facilitating rapid access to Polaris. The P.G.-C. lab is funded by the Institut Pasteur, the National French Research Agency (ANR; ANR-22-CE11-0003 and ANR-24-CE15-6625), and the European Union RESILIENCE-R-2023 (n°101168024). The O.S. lab is funded by Institut Pasteur, Fondation pour la Recherche Médicale (FRM), ANRS, the Vaccine Research Institute (VRI) (ANR-10-LABX-77), Labex IBEID (ANR-10-LABX-62-IBEID), the HERA projects DURABLE (grant 101102733), and LEAPS. J.P. is supported by DURABLE. The J.G.-A. lab is funded by CSIC grant 202120E079; grant CNS2022-135511 from the Spanish Ministry of Science, Innovation, and Universities (MCIU)/Spanish Research Agency (AEI)/10.13039/501100011033 and the European Union NextGenerationEU/PRTR to promote the consolidation of research; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBER-INFEC), co-financed with FEDER funds; and Spanish MCIU/AEI/10.13039/501100011033 grant . J.G.-A. and M.E. are also funded by the European Union RESILIENCE-R-2023 (n°101168024), funded by the European Union. Views and opinions expressed are those of the author(s) and do not necessarily reflect those of the European Union or the European Defence Fund. Neither the European Union nor the granting authority can be held responsible for them. This is related to the project RESILIENCE-R-2023 (n°101168024). J.S.H. and A.M.L. are funded by the European Union’s Horizon 2020 research and the innovation program under Marie Sklodowska Curie Grant 860592 and Deutsche Forschungsgemeinschaft (DFG, German Research Foundation; grants SFB1027/B7 and INST256/539-1). The P.C. and M.M. lab is funded by the National French Research Agency (ANR-24-CE15-6625 and France 2030 funding ANR-24-CHBS-0003). L.P. was supported by the UCL Birkbeck MRC DTP. R.B. was funded by the MRC Laboratory for Molecular Cell Biology PhD program. J.M. was supported by the MRC Laboratory for Molecular Cell Biology (MC_UU_00012/7)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Contribución de congreso (ConferenceOutput)

Isolation of CCHFV in Spanish ticks & confirmation of specific antibodies in animals

  • Ruiz-Fons, Francisco
Resumen del trabajo presentado a la 2nd ISIDORe Users’ Conference, celebrada del 11 al 12 de junio de 2025 en Paris., This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No. 101046133., No
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

An ACE2-Fc decoy produced in glycoengineered plants neutralizes ancestral and newly emerging SARS-CoV-2 variants and demonstrates therapeutic efficacy in hamsters

  • Föderl-Höbenreich, Esther
  • Izadi, Shiva
  • Hofacker, Lara
  • Kienzl, Nikolaus F.
  • Castilho, Alexandra
  • Strasser, Richard
  • Tarrés Freixas, Ferran
  • Cantero Portillo, Guillermo
  • Roca, Núria
  • Pérez Maíllo, Mónica
  • Lorca-Oró, Cristina
  • Usai, Carla
  • Segalés, Joaquim
  • Vergara-Alert, Júlia
  • Mach, Lukas
  • Zatloukal, Kurt
Newly emerging SARS-CoV-2 variants of concern (VOCs) continue to drive COVID-19 waves and are typically associated with immune escape and increased resistance to current therapeutics including monoclonal antibodies. By contrast, VOCs still display strong binding to the host cell receptor ACE2. Consistent with these properties, we have now found that a soluble ACE2-Fc decoy produced in glycoengineered plants effectively neutralizes different SARS-CoV-2 isolates and exhibits even increased potency against VOCs as compared to an ancestral virus strain. In a golden Syrian hamster model, therapeutic intranasal delivery of ACE2-Fc effectively reduced weight loss and SARS-CoV-2 replication in the lungs when administered 24 h post-inoculation. This protective effect was not observed upon treatment of the infected animals with a non-binding ACE2-Fc mutant, demonstrating that the plant-derived ACE2-Fc decoy interferes specifically with the attachment of the virus to host cells. The results obtained provide support for further development of decoy-based antiviral approaches by plant molecular pharming., We thank Ulrike Vavra, Katharina Wolf and David Niedermayer for assistance with ACE2-Fc purification and characterization and Vinny Kunnummel for plant propagation and maintenance. We are grateful to Florian Krammer for his advice on the design of the in vivo study. This work was supported by funds from BOKU University and a Transnational Access Grant provided by ISIDORe (funded by the European Union’s Horizon Europe research and innovation program under grant agreement No. 101046133) to Zatloukal Innovations GmbH. This research was funded in part by the Austrian Science Fund (FWF) [W 1224/Grant https://doi.org/10.55776/W1224; P 31920/Grant https://doi.org/10.55776/P31920; P 35292/Grant https://doi.org/10.55776/P35292]. For open access purposes, the authors have applied a CC BY public copyright license to any accepted manuscript version arising from this submission. The SARS-CoV-2 variant hCoV-19/France/GE1973/2020, clade G, D614G (S) was supplied through the European Virus Archive goes Global (EVAg) platform, a project that has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 653316., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

“Be sustainable”: EOSC‐Life recommendations for implementation of FAIR principles in life science data handling

  • David, Romain
  • Lancelotti, Carla
  • Gribbon, Philip
Includes supplementary materials for the online appendix., The main goals and challenges for the life science communities in the Open Science framework are to increase reuse and sustainability of data resources, software tools, and workflows, especially in large‐scale data‐driven research and computational analyses. Here, we present key findings, procedures, effective measures and recommendations for generating and establishing sustainable life science resources based on the collaborative, cross‐disciplinary work done within the EOSC‐Life (European Open Science Cloud for Life Sciences) consortium. Bringing together 13 European life science research infrastructures, it has laid the foundation for an open, digital space to support biological and medical research. Using lessons learned from 27 selected projects, we describe the organisational, technical, financial and legal/ethical challenges that represent the main barriers to sustainability in the life sciences. We show how EOSC‐Life provides a model for sustainable data management according to FAIR (findability, accessibility, interoperability, and reusability) principles, including solutions for sensitive‐ and industry‐related resources, by means of cross‐disciplinary training and best practices sharing. Finally, we illustrate how data harmonisation and collaborative work facilitate interoperability of tools, data, solutions and lead to a better understanding of concepts, semantics and functionalities in the life sciences., This research is mainly a product of the EOSC‐Life European programme funding from the European Union's Horizon Europe Research and Innovation Programme under grant agreement No. 824087. Complementary support was provided through: EU funded project AgroServ (grant agreement No. 101058020), EU funded project BY‐COVID (grant agreement No. 101046203), EU funded project DANUBIUS‐IP (grant agreement No. 101079778), EU funded project EMPHASIS‐GO (grant agreement No. 101079772), EU funded project FAIRplus (IMI grant agreement No. 802750), EU funded project FAIRsharing (Wellcome grant agreement No. 212930/Z/18/Z), EU funded project ISIDORe (grant agreement No. 101046133), EU funded project Precision Toxicology (grant agreement No. 965406), UKRI DASH (grant agreement No. MR/V038966/1). Special thanks to T. Biro and her radical collaboration team from Research Data Alliance who gave us great inspiration on how to lead this radical collaboration work.Thanks are also due to Martina Esdaile for proofreading the final version of the manuscript. Open access funding enabled and organized by Projekt DEAL.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Differential impact of porcine reproductive and respiratory virus and swine Influenza A virus infections on respiratory Lymph Nodes B cells and macrophages

  • Hervet, C.
  • Perrin, A.
  • Renson, P.
  • Deblanc, C.
  • Muñoz, M.
  • Meurens, F.
  • Argilaguet, Jordi
  • Simon, G.
  • Bourry, O.
  • Maisonnasse, P.
  • Bertho, N.
Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) has a profound impact on the swine industry due to its ability to persist in infected animals. The PRRSV family exhibits considerable genetic variability, with PRRSV-1 and PRRSV-2 now classified as two distinct species (Betaarterivirus suid 1 and 2). Interestingly, both species - and their corresponding attenuated vaccine strains - can persist for months, in part by delaying the appearance of neutralizing antibodies. Leveraging recently developed tools for in-depth analysis of the previously poorly characterized porcine inverted lymph node (LN), we investigated early events in LN B cell maturation during PRRSV-1 infection and compared them to those induced by acute swine influenza A virus infection. We highlighted PRRSV-specific mechanisms, including PD-L1 upregulation in efferent macrophages, the presence of extrafollicular centrocytes, and the influx of inflammatory monocytes/macrophages. These findings are consistent with previous observations in PRRSV-2 infections and may therefore reflect conserved immune evasion mechanisms across PRRSV strains., This work was supported by the European Union’s Infrastructure Program VetBioNet (INFRA-2016–1; Nº731014) and the Horizon Europe research and innovation program ISIDORe (Grant Agreement No. 101046133). This publication reflects the views only of the authors, and does not necessarily represent those of the European Commission (EC). The EC is not responsible for any use that may be made of the information contained herein., info:eu-repo/semantics/acceptedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Boosting Vaccine Research: The 16-Year Journey of TRANSVAC Vaccine Infrastructure

  • Martin, William
  • Luís, Catarina
  • Jungbluth, Stefan
  • Slezak, Monika
  • Verreck, Frank A. W.
  • Spiegel, Holger
  • Guzman, Carlos A.
  • Roldão, António
  • Carrondo, Manuel J. T.
  • Van der Ley, Peter
  • Segalés, Joaquim
  • Dockrell, Hazel M.
  • Ho, Mei Mei
  • Pedersen, Gabriel K.
  • Lawrenz, Maria
  • Olesen, Ole F.
TRANSVAC represents a long-running effort to accelerate the development of novel vaccines by integrating institutions from across Europe under a single collaborative framework. This initiative has empowered the global vaccine community since 2009 including contributing toward the development and optimization of vaccine candidates as well as the provision of new adjuvants, research protocols, and technologies. Scientific services were provided in support of 88 different vaccine development projects, and 400 professionals attended TRANSVAC training events on various vaccine-related topics. Here, we review the accomplishments of the TRANSVAC consortia and analyze the continued needs of academic and industrial vaccine developers in Europe. The findings highlight the benefits of coordination across different sectors, both through research infrastructures such as TRANSVAC and other mechanisms, to address the current and future global health challenges and ensure that European vaccine developers have the support required to successfully compete in the global market., TRANSVAC was supported by the EU FP7 project TRANSVAC (FP7-INFRASTRUCTURES-2008-228403). TRANSVAC2 received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement no. 730964. ISIDORe received funding from the European Union’s Horizon Europe research and innovation program under grant agreement number 101046133., info:eu-repo/semantics/publishedVersion